ArticleJournal of controlled release : official journal of the Controlled Release Society2025
Enhanced safety and potency in local angiogenic growth factor delivery via aptamer functionalization of hydrogels.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aptamer-Based Delivery Systems for VEGF and NGF Modulation in Ocular Therapies.Advanced healthcare materials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hydrogels for drug delivery, particularly for the delivery of potent protein therapeutics, have been extensively studied across various biomedical applications. Because hydrogels act as reservoirs for localized drug release, this delivery approach is generally not expected to cause the same severe systemic toxicity observed with systemic drug administration. However, the current study has shown for the first time that the implantation of native hydrogels loaded with vascular endothelial growth factor (VEGF) induced acute severe hemorrhage and animal mortality in a femoral vessel micropuncture (MP) surgery model. In contrast, no side effects were observed when hydrogels functionalized with anti-VEGF aptamers and loaded with the same amount of VEGF were implanted. Furthermore, the presence of the aptamers in the hydrogels did not compromise the ability of VEGF to promote new blood vessel growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.